Cloud group

Cloud Group

Acute stroke care and treatments

We develop new stroke treatments for acute stroke care and novel treatments to aid stroke recovery.

We do this by conducting randomized controlled trials of new treatments for acute stroke care, secondary prevention of stroke and novel treatments to improve stroke recovery.

We also participate in the National Stroke Registry (AuSCR) which informs national stroke service quality improvement in stroke care.

-

In the news

Trauma drug promise in cerebral amyloid angiopathy

Treatment with the anti-fibrinolytic drug, tranexamic acid (TXA), in a pre-clinical model of cerebral amyloid angiopathy blocked generation in a  new study published in key stroke journal.

Read more

-

Group Leader

Leave this here so that Accordion nested does not detect this CT as not existing.

Current Trials

Name of Trial Type of trial
Modafinil In Debilitating Fatigue After Stroke 2 (MIDAS 2) Phase III Randomised, double blind Clinical Trial
Trial of EXenatide in Acute Ischaemic Stroke (TEXAIS) Phase II Randomised, open-label clinical trial
Stopping Haemorrhage With Tranexamic Acid cOmmenced Prehospital - in a Mobile Stroke Unit (STOP-MSU) Randomised Clinical Trial
Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction (CHARM) Phase III Randomised, double blind Clinical Trial
Phase II Randomised Controlled Trial
Interventional
Randomised controlled clinical trial - Interventional

Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT)

Phase III Randomised Controlled Trial

Project

A network of sites and ‘up-skilled’ therapists to deliver best practice stroke rehabilitation of the upper limb

This NHMRC Partnership project includes clinicians, health providers, consumers, researchers and academics, who aim to increase access to best-practice stroke rehabilitation of the arm and thus achieve better outcomes for people who experience a stroke. We will employ knowledge transfer methods to change clinician behaviour and create a network of sites and ‘up-skilled’ therapists to deliver best-practice rehabilitation. Effective therapies are available to improve hand function. However, our recent national survey found that stroke survivors who experience loss of touch sensation and impaired hand function are not currently receiving recommended best-practice therapy. We developed a ‘knowledge transfer’ intervention to target this evidence-practice gap and the unmet rehabilitation needs of survivors. The intervention is guided by the Theoretical Domains Framework and Behaviour Change Wheel. It targets the delivery of science-based rehabilitation that requires specific knowledge and skill of the therapist; an application of knowledge translation that is virtually untested in our field. We will use a pragmatic before-after design to test the effectiveness of our knowledge transfer intervention to change clinician behaviour and improve outcomes. We will investigate current-generalist and specialist modes of delivery as well as cost-effectiveness. The implementation intervention will be an exemplar for translating recommended science-based rehabilitation interventions to the clinic and community. The project will deliver a knowledge translation hub, specialist delivery clinics, and a community of up-skilled therapists embedded in a range of healthcare settings. Together we will establish an allied health network across Australia for translational activities in stroke rehabilitation and establish and measure the potential benefits of a ‘new’ translational approach, which can be used to introduce other new therapeutic programs as translational activities in the future.

Current project funding

  • 2017-20 NHMRC Partnership Grant  APP1134495 A network of sites and ‘up-skilled’ therapists to deliver best practice stroke rehabilitation of the upper limb.

Selected recent publications

See most recent PubMed listed publications. The feed below is from Prof Cloud's Monash profile.